science wire

« BACK

Pharmacology



Results 2151 - 2200 of 2235.
« Previous 1 ... 40 41 42 43 44 ... 45 Next »


Pharmacology - Health - 16.10.2010
Long-term data show Novartis once-yearly Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis
Long-term data show Novartis once-yearly Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis Aclasta reduced the risk of new spine fractures by 52% over six years versus patients who stopped treatment after three years New data from six-year study validate Aclasta safety profile and support long-term use of annual infusions in patients with postmenopausal osteoporosis More than one million Aclasta infusion

Pharmacology - Health - 12.10.2010
Novartis affirms commitment to sustain efforts toward final elimination of leprosy in partnership with World Health Organization
Novartis affirms commitment to sustain efforts toward final elimination of leprosy in partnership with World Health Organization · Novartis signs Memorandum of Understanding with the World Health Org

Health - Pharmacology - 11.10.2010
Phase III Novartis data show potential benefit of Afinitor plus Sandostatin LAR in patients with advanced neuroendocrine tumors
Phase III Novartis data show potential benefit of Afinitor plus Sandostatin LAR in patients with advanced neuroendocrine tumors Everolimus plus octreotide LAR extended time without tumor growth from

Pharmacology - Health - 05.10.2010
Novartis discontinues development of two investigational compounds reflecting enhanced focus on portfolio prioritization and productivity
Novartis discontinues development of two investigational compounds reflecting enhanced focus on portfolio prioritization and productivity Human Genome Sciences and Novartis to stop further developmen

Pharmacology - Economics / Business - 30.09.2010
Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney’s Office
Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney's Office Novartis Pharmaceuticals Corporation reaches resolution with US Attorney's

Health - Pharmacology - 24.09.2010
Novartis drug Tasigna recommended for approval in European Union to treat patients with newly diagnosed Ph+ chronic myeloid leukemia
Novartis drug Tasigna recommended for approval in European Union to treat patients with newly diagnosed Ph+ chronic myeloid leukemia Positive CHMP opinion based on pivotal trial showing Tasigna super

Health - Pharmacology - 24.09.2010
Novartis receives EU approval recommendation for TOBI Podhaler , a fast and simple therapy that helps reduce treatment burden for cystic fibrosis patients
Novartis receives EU approval recommendation for TOBI Podhaler , a fast and simple therapy that helps reduce treatment burden for cystic fibrosis patients CHMP supports approval of TOBI Podhaler, a new dry powder form of tobramycin for treating chronic P. aeruginosa lung infection in cystic fibrosis patients over six Data show new formulation reduces administration time by 72% compared to TOBI, with same efficacy and using more convenient

Health - Pharmacology - 22.09.2010
Novartis gains FDA approval for a novel multiple sclerosis treatment
Novartis gains FDA approval for a novel multiple sclerosis treatment
Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression Gilenya is the first approved oral treatment indicated for relapsing forms of MS in the US, a major advance for people with this disease.

Health - Pharmacology - 22.09.2010
Novartis drug SOM230 is first medical therapy to show efficacy in a Phase III trial in Cushing’s disease, a debilitating hormonal disorder
Novartis drug SOM230 is first medical therapy to show efficacy in a Phase III trial in Cushing's disease, a debilitating hormonal disorder SOM230 reduced urinary free cortisol (UFC) levels in majority of patients; 26% of patients randomized to SOM230 900µg achieved normal UFC levels With reduced UFC levels, clinical symptoms improved including lower blood pressure, total cholesterol and weight loss Cushing's disease is caused by a pituitary tumo

Pharmacology - Health - 19.09.2010
Onbrez Breezhaler is superior to salmeterol in reducing breathlessness for patients with COPD
Novartis study shows Onbrez Breezhaler is superior to salmeterol in reducing breathlessness for patients with COPD Phase III INSIST study shows once-daily Onbrez Breezhaler gave better 24-hour bronchodilation than twice-daily salmeterol , a current mainstay of treatment Data show Onbrez Breezhaler significantly reduced use of rescue medication in patients with chronic obstructive pulmonary disease (COPD) New results provide further evidence that

Pharmacology - Health - 15.09.2010
Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis, a rare, life-threatening blood cancer
Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis, a rare, life-threatening blood cancer Myelofibrosis is a blood cancer characterized by bone marrow failure, enlarged spleen, poor quality of life and shortened survival Phase I/II data published in NEJM demonstrate clinical benefits of JAK1 and JAK2 inhibitor INC424, including reduction of spleen size and alleviation of debilitating symptoms Nova

Health - Pharmacology - 12.09.2010
Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease
Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease Pivotal data show that the large majority of infants vaccinated with N

Pharmacology - Health - 03.09.2010
Novel antimalarial drug candidate
Novartis announced today that scientists at the Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria.

Pharmacology - Health - 27.08.2010
Novartis drug Tasigna approved in Switzerland after fast-track review for treatment of patients with newly diagnosed Ph+ CML
Novartis drug Tasigna approved in Switzerland after fast-track review for treatment of patients with newly diagnosed Ph+ CML Pivotal Phase III trial data demonstrate superiority to standard of care G

Health - Pharmacology - 23.08.2010

Pharmacology - 23.07.2010
Sandoz leads the way with first generic version of ’gold standard’ anti-thrombotic Lovenox [1]
Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox Sandoz is the first company to receive US approval to market a more affordable generic version of the leadin

Pharmacology - 20.07.2010
Novartis receives approval in China for Rasilez, a first-in-class direct renin inhibitor for high blood pressure, the leading preventable cause of death in China
Novartis receives approval in China for Rasilez, a first-in-class direct renin inhibitor for high blood pressure, the leading preventable cause of death in China Rasilez provides significant blood pr

Pharmacology - 14.07.2010
Plaintiffs and Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, agree to resolve all gender discrimination claims associated with class action
Plaintiffs and Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, agree to resolve all gender discrimination claims associated with class action · Agreement reached between Novarti

Pharmacology - 01.07.2010
Phase III study shows Novartis drug Afinitor more than doubles time without tumor growth in advanced pancreatic NET patients
Phase III study shows Novartis drug Afinitor more than doubles time without tumor growth in advanced pancreatic NET patients Everolimus extended median progression-free survival from 4.6 to 11.0 months vs.

Pharmacology - 18.06.2010
FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Glivec
FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Glivec In head-to-head trial, Tasigna reduced leukemia-causing protein faster than Glivec, resulting in lower rates of cancer progression even as early as 12 months Regulatory submissions under way worldwide, with applications currently filed in the EU, Switzerland and Japan Basel, June 17, 2010 - Following a priority review, the US Fo

Pharmacology - 18.06.2010
New Phase II study in gout patients shows Novartis ACZ885 prevented acute flares better than standard anti-inflammatory therapy
New Phase II study in gout patients shows Novartis ACZ885 prevented acute flares better than standard anti-inflammatory therapy ACZ885 significantly reduced rate of acute flares up to 75% vs.

Pharmacology - 11.06.2010
FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS
FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS Committee voted in favor of approval of FTY720 (fingolimod), as treatment in relapsing remitting multiple sclerosis, affirming the drug's positive benefit/risk profile FTY720, potentially first in a new class of MS therapy, represents a significant advance as an efficacious oral treatment for people with relapsing r

Pharmacology - 05.06.2010
Study at ASCO shows Novartis drug Afinitor first to shrink SEGA brain tumors in children and adults with tuberous sclerosis
Study at ASCO shows Novartis drug Afinitor first to shrink SEGA brain tumors in children and adults with tuberous sclerosis Phase II study shows meaningful reduction in brain tumor size in 75% of patients with subependymal giant cell astrocytomas (SEGAs) from baseline to six months SEGAs are benign brain tumors associated with tuberous sclerosis (TS) that primarily affect children and adolescents and can cause severe brain swelling No patient de

Pharmacology - 05.06.2010
Adding Novartis drug Zometa to chemotherapy significantly improved overall survival in study of newly diagnosed multiple myeloma patients
View all media releases June 05, 2010 14:15 CET Adding Novartis drug Zometa to chemotherapy significantly improved overall survival in study of newly diagnosed multiple myeloma patients This press release is not intended for United Kingdom news media Phase III data show Zometa, a bone-targeted agent, provided significant clinical anticancer benefit and significantly reduced risk of skeletal-related events Survival advantage observed with Zometa

Pharmacology - 04.06.2010
New data at ASCO show Novartis drug Tasigna surpasses Glivec in slowing disease progression for newly diagnosed CML patients
View all media releases June 04, 2010 07:15 CET New data at ASCO show Novartis drug Tasigna surpasses Glivec in slowing disease progression for newly diagnosed CML patients 18-month median follow-up from the first head-to-head comparison of these two oral therapies to be presented Monday, June 7 at ASCO In this study, Tasigna produced deeper molecular responses and significantly reduced progression to advanced disease, resulting in fewer deaths

Health - Pharmacology - 03.06.2010
Pivotal Phase III trial of Novartis drug Afinitor met primary endpoint in study of patients with advanced pancreatic neuroendocrine tumors
Pivotal Phase III trial of Novartis drug Afinitor met primary endpoint in study of patients with advanced pancreatic neuroendocrine tumors RADIANT-3 study results show everolimus significantly extend

Health - Pharmacology - 02.06.2010
Data at ASCO show promise of Novartis drugs for patients with life-threatening diseases like CML, multiple myeloma and breast cancer
Data at ASCO show promise of Novartis drugs for patients with life-threatening diseases like CML, multiple myeloma and breast cancer Pipeline data, including panobinostat (LBH589), PI3K Inhibitors BE

Pharmacology - Health - 27.05.2010
Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint
Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint Basel, May 27, 2010 - Novartis announced today that patupilone (EPO906) did not show a significant overall survival advantage in a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy The comparator arm in the trial was Doxil /Caelyx (pegylated liposomal doxorubicin).

Pharmacology - 25.05.2010
Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapy
Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapy US Food and Drug Administration (FDA) extends priority r

Health - Pharmacology - 22.05.2010
Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes
Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes Study shows around 40% of ranibizumab patients substantially impr

Health - Pharmacology - 23.04.2010
Novartis gains new indication for Diovan for the treatment of children and adolescents with high blood pressure in the EU
Novartis gains new indication for Diovan for the treatment of children and adolescents with high blood pressure in the EU New indication brings the world's number one selling high blood pressure medi

Pharmacology - Health - 22.04.2010
Novartis receives US FDA approval for Zortress® (everolimus) to prevent organ rejection in adult kidney transplant recipients
Novartis receives US FDA approval for Zortress® (everolimus) to prevent organ rejection in adult kidney transplant recipients Zortress offers kidney transplant recipients a new option for preventing

Pharmacology - 22.04.2010
Novartis receives US FDA approval for Zortress (everolimus) to prevent organ rejection in adult kidney transplant recipients
Novartis receives US FDA approval for Zortress (everolimus) to prevent organ rejection in adult kidney transplant recipients Zortress offers kidney transplant recipients a new option for preventing o

Pharmacology - 20.04.2010
Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity
Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation , growth and productivity Net sales up 25% (+18% in constant currencies, or cc) to US

Pharmacology - 19.04.2010
Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD
Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD ·         Sandoz gains rights to three promising development projects, as well as t

Pharmacology - Health - 13.04.2010
Novartis investigational multiple sclerosis therapy Gilenia®* (FTY720) shown to reduce relapse rates regardless of treatment history
Basel, April 13, 2010 - Data presented at the American Academy of Neurology (AAN) annual meeting add to the accumulating evidence of the positive benefit/risk profile of Gilenia, a potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis (MS).

Pharmacology - Health - 13.04.2010
Novartis investigational multiple sclerosis therapy Gilenia * (FTY720) shown to reduce relapse rates regardless of treatment history
Novartis investigational multiple sclerosis therapy Gilenia * (FTY720) shown to reduce relapse rates regardless of treatment history New extension data show Gilenia effect sustained over two years; also highlights potential benefits of switching from interferon beta-1a Basel, April 13, 2010 - Data presented at the American Academy of Neurology (AAN) annual meeting add to the accumulating evidence of the positive benefit/risk profile of Gilenia, a potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis (MS).

Pharmacology - 18.03.2010
Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease
Basel, March 18, 2010 - Novartis announced today that the European Commission (EC) granted a Marketing Authorization for Menveo ® (Meningococcal Group A, C, W135 and Y conjugate vaccine) in all 27 European member states. Menveo is indicated for the active immunization of adolescents (from 11 years of age) and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.

Health - Pharmacology - 18.03.2010
Novartis receives approval in the European Union for Menveo , first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease
Novartis receives approval in the European Union for Menveo , first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease Meningococcal disease is a major cause of bacterial

Pharmacology - 16.03.2010
Exploratory trial shows no incremental benefit of aliskiren add-on therapy in improving changes to cardiac shape in heart attack patients
Exploratory trial shows no incremental benefit of aliskiren add-on therapy in improving changes to cardiac shape in heart attack patients ·       Trial assessed addition of aliskiren to help limit changes to the heart's shape and function in patients after heart attack (post-myocardial infarction) ·       A small numerical reduction in cardiac volume from adding aliskiren to standard therapy seen in echocardiogram results, but not statistically

Pharmacology - 14.03.2010
NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance
NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance NAVIGATOR study involved more than 9,000 patients, making it one of the largest and longest global trials to date in pre-diabetic patients Basel, March 14, 2010 - Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

Pharmacology - 10.03.2010
Novartis announces USD 5 billion bond issue
These notes are registered with the U.S. Securities and Exchange Commission under an automatic shelf registration statement filed by Novartis in 2008.

Economics / Business - Pharmacology - 26.02.2010
Shareholders approve all proposed resolutions of Novartis Board of Directors
Shareholders approve 14 th consecutive dividend increase to CHF 2.20 (+5%) per share for 2010, representing a payout of approximately 55% of net income from continuing operations, marking cont

Pharmacology - 22.02.2010
Novartis receives FDA approval of Menveo®, a vaccine to prevent meningococcal disease
Basel, February 22, 2010 - Novartis announced that Menveo® (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by the US Food and Drug Administration (FDA) for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people 11 to 55 years of age .

Pharmacology - 22.02.2010
Novartis oral multiple sclerosis development compound Gilenia®* (FTY720) granted US priority review status
Basel, February 22, 2010 - Gilenia®* (FTY720, fingolimod) has been granted priority review status by the US Food and Drug Administration (FDA), which accepted the regulatory submission made in December 2009 for this medicine. Once-daily Gilenia  (0.5 mg) has the potential to become the first approved oral therapy for the treatment of multiple sclerosis (MS).

Pharmacology - 19.02.2010
Novartis drug Tasigna® receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia
Basel, February 19, 2010 - Novartis announced today that Tasigna® (nilotinib) has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. FDA priority review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists.
« Previous 1 ... 40 41 42 43 44 ... 45 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |